John Maraganore, Alnylam CEO (Scott Eisen/Bloomberg via Getty Images)

With lumasir­an on the FDA's doorstep, Al­ny­lam reads out new PhI­II da­ta in PH1

Just over a month away from its De­cem­ber PDU­FA date, Al­ny­lam flaunt­ed new da­ta from two Phase III stud­ies to back lumasir­an in pri­ma­ry hy­per­ox­aluria …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.